Track apps

Roundup: Korean researchers are developing biosensors to track real-time serotonin levels and more memories

Korean researchers are developing a biosensor to measure serotonin levels in real time

A research team from the Korea Biosciences and Biotechnology Research Institute has developed a biosensor that can track serotonin levels in real time for the diagnosis of depression.

Depression, which affects more than a million South Koreans, is believed to be caused in part by imbalances in neurotransmitters in the human body, such as serotonin, which help stabilize mood. Typically, serotonin levels are analyzed by mass spectrometry of blood samples, which can be time consuming.

To accelerate this process, KRIBB researchers have developed a bio-probe that reacts selectively to serotonin and a nano-biosensor capable of detecting even traces of serotonin by combining it with highly conductive nanofibers.

The sensor reacts with serotonin and generates an electrical signal which is used to measure the concentration of serotonin.

In an evaluation of its effectiveness, the biosensor showed a high level of reliability in detecting serotonin in artificial body fluids. Results of the assessment were published in the journal Nano Convergence.

“Real-time monitoring of serotonin allows us to observe the effect of serotonin on body function, as well as the change in secretion in response to harmful external stimuli,” said Dr Oh-seok Kwon, research manager.


Lunit Gets Taiwan Green Light for AI Mammography Solution

South Korean medical AI startup Lunit has received approval from the Taiwan Food and Drug Administration for its AI mammography solution.

Its Lunit INSIGHT MMG has been cleared for sale in Taiwan as a Class 2 medical device.

The solution uses AI to detect suspicious lesions in mammography images with 96% accuracy.

The company also received similar regulatory approvals for INSIGHT MMG in the United States last year and in Canada in June this year.


Singapore’s National University Cancer Institute Unveils Cancer Treatment Cost Calculator

The National University Cancer Institute in Singapore has partnered with health tech startup Bot MD to create a chemotherapy and cancer treatment cost calculator.

The NCIS Chemotherapy Cost Calculator or ChemoCalc provides an instant estimate of a patient’s monthly expenses based on their prescribed cancer treatment, residency status, level of resources, and eligibility for various government grant programs .

The launch of this app comes ahead of upcoming changes to the MediShield Life reimbursement model, which will only cover a positive list of clinically proven, cost-effective cancer treatments.

“In light of upcoming policy changes from the Ministry of Health, we wanted to create a simple and effective tool that would help our patients understand the cost of their treatment, so that they could be able to make decisions about their care, factor those costs into their budgets, and seek help quickly if the costs are prohibitive for them,” explained Dr. Jen Wei Ying, associate consultant in the NCIS Department of Hematology-Oncology.

Chinese insurtech company Waterdrop launches virtual AI assistant for insurers

Beijing-based insurance technology company Waterdrop recently unveiled an AI-based virtual assistant for insurers.

According to a press release, the Waterdrop Assistant is a human-like digital assistant that helps online insurance service teams with tasks such as data processing and analysis, online user management and Client services.

He is able to conduct simple conversations with clients, record and collate their protection needs and intention to purchase insurance. According to the company, the digital assistant knows well over 100 insurance products in Waterdrop’s data library.

Since launch, Waterdrop Assistant has processed 86% of user sessions with 97% accuracy for intent recognition, freeing approximately 37% of customer service manpower and increasing the rate renewal of policies.


Medical imaging company United Imaging Healthcare debuts in Shanghai

Chinese medical imaging device and equipment supplier United Imaging Healthcare has gone public in China through a listing on the Shanghai Stock Exchange’s Science and Technology Innovation Board.

Net proceeds from its $1.6 billion IPO will go towards next-generation product research and development, industrialization projects, and marketing service network projects.

United Imaging’s products have been adopted by medical and research institutions in more than 40 countries around the world, including the United States, Japan, Italy and New Zealand.